RPRX250117P37500
- 0.00
- 0.000.00%
Royalty Pharma Newsroom
TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $42
TD Cowen Initiates Royalty Pharma(RPRX.US) With Buy Rating, Announces Target Price $42
TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $42
TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $42
Royalty Pharma (RPRX) Gets a Buy From TD Cowen
BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $39
BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $39
Strong Buy Rating for Royalty Pharma: Robust Revenue Growth and Promising Pipeline
Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $51
Royalty Pharma Is Maintained at Buy by Citigroup
Royalty Pharma Analyst Ratings
Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $51
TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $42
Goldman Sachs Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $51
Royalty Pharma Analyst Ratings
Goldman Sachs Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $51
Buy Rating Affirmed for Royalty Pharma Amidst Strong Financials and Positive Growth Outlook
Analysts Offer Insights on Healthcare Companies: CSL (OtherCMXHF) and Royalty Pharma (RPRX)
Analysts Are Bullish on These Healthcare Stocks: Royalty Pharma (RPRX), Arcellx Inc (ACLX)
Royalty Pharma (RPRX) Receives a Buy From Morgan Stanley